Tuvonralimab and Iparomlimab before surgery for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer that is considered borderline removable (the doctor thinks it might be possible to remove it with complex surgery).
- You have not had any previous treatment for your cancer (no chemotherapy, radiation, or other drugs).
- Your cancer is locally advanced without spreading to distant organs (like the liver or lungs).
- You are in good overall health (able to do daily activities without help, with a performance status of 0 or 1).
- Your blood counts and organ function (kidneys, liver) are within acceptable ranges.
- You agree to use effective contraception if applicable, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (ivonescimab, liposomal irinotecan, and 5-FU/LV) to shrink bile duct or gallbladder tumors enough so they can be surgically removed. It is for people who have not had any prior treatment for their cancer.
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy (GemOX) and lenvatinib can shrink tumors enough so that bile duct or gallbladder cancers that could not be removed initially become eligible for surgery. It is an option for people with advanced but not yet spread cancer who have not received prior treatment.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.